US Patent

US11819487 — Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib

Method of Use · Assigned to SpringWorks Therapeutics Inc · Expires 2041-02-17 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating plexiform neurofibromas associated with neurofibromatosis type 1 in pediatric patients by administering mirdametinib.

USPTO Abstract

The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

mirdametinib (MIRDAMETINIB)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4130`	—	mirdametinib
`U-4130`	—	mirdametinib
`U-4130`	—	mirdametinib

Patent Metadata

Patent number: US11819487
Jurisdiction: US
Classification: Method of Use
Expires: 2041-02-17
Drug substance claim: No
Drug product claim: No
Assignee: SpringWorks Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.